Saturday 7 June 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Researchers discover link between gene and cause of blindness

Researchers discover link between gene and cause of blindness

17 November 2008

Macular degeneration is one of the leading causes of blindness in people over the age of 60 and a trans-Atlantic study may have found the culprit behind this problem. Researchers from the University of Southampton in the UK and the University of Iowa in the USA believe the Serping 1 gene is responsible for age-related macular degeneration (AMD). This discovery is expected to help scientists find better treatments and improve screening processes for patients. The finding was recently published in the on-line version of The Lancet.

The researchers found the gene in 25% of the people participating in the study. Past data have indicated that almost 66% of octogenarians suffer from AMD and over 10% are left blind by the disease. The area at the back of the eye is what helps people see objects in fine detail. AMD affects this area. The researchers postulate that 33% of the population over the age of 75 will eventually suffer from AMD.

The Southampton team said the annual economic burden from the disease could reach L80.0 million ($125.5 million) in the UK alone. According to the researchers, this figure could rise as the number of older people grows. The research also showed that the costs of healthcare increased seven-fold for AMD sufferers versus non-AMD patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Latin America must increase its investment in health to ensure universal and quality access
Pharmaceutical
Latin America must increase its investment in health to ensure universal and quality access
6 June 2025
Pharmaceutical
Ardelyx names new chief business and human resources officers
6 June 2025
Biotechnology
Sobi and Apellis data underscore Aspaveli potential
6 June 2025
Biotechnology
Otsuka sibeprenlimab Phase III trial shows 51% reduction in proteinuria
6 June 2025
Biotechnology
Kelun-Biotech announces US$250 million placement
6 June 2025
Biotechnology
Rapid expansion predicted for Friedreich's ataxia market
6 June 2025
Biotechnology
ImmunoPrecise jumps on reported vaccine breakthrough
6 June 2025

Company Spotlight

A clinical-stage company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze